Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis

BACKGROUND: Nivolumab plus chemotherapy (NC) was recently approved as the first-line intervention for human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer (GC/GEJC). Moreover, in the latest KEYNOTE-859 (NCT03675737), pembrolizumab plus chemotherapy (PC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Zhu, Hong, Wu, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624011/
https://www.ncbi.nlm.nih.gov/pubmed/37928895
http://dx.doi.org/10.1177/17562848231207200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624011/
https://www.ncbi.nlm.nih.gov/pubmed/37928895
http://dx.doi.org/10.1177/17562848231207200

Ejemplares similares